Andreas Hochhaus

Department for Hematology and Medical Oncology, Jena University Hospital

Research Area

Biography

Andreas Hochhaus has not added Biography.
If you are Andreas Hochhaus and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 2	2019

Other Publications

Article	Year
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia\| PubMed ID: 19641527	2009
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell cycle (Georgetown, Tex.)\| PubMed ID: 21220945	2011
[Chronic myeloid leukemia]. Deutsche medizinische Wochenschrift (1946)\| PubMed ID: 21960328	2011
Educational session: managing chronic myeloid leukemia as a chronic disease. Hematology. American Society of Hematology. Education Program\| PubMed ID: 22160024	2011
Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders. Onkologie\| PubMed ID: 22286586	2012
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. British journal of haematology\| PubMed ID: 22409268	2012
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood\| PubMed ID: 22411871	2012
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. BMC blood disorders\| PubMed ID: 22871019	2012
[Tailored management of chronic myeloid leukemia]. Der Internist\| PubMed ID: 23371258	2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood\| PubMed ID: 23502220	2013
Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Annals of hematology\| PubMed ID: 23558906	2013
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clinical pharmacology : advances and applications\| PubMed ID: 23788844	2013
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Journal of cancer research and clinical oncology\| PubMed ID: 23942795	2013
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. Journal of cancer research and clinical oncology\| PubMed ID: 24057647	2013
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World journal of gastroenterology\| PubMed ID: 25400468	2014
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. Annals of hematology\| PubMed ID: 25814079	2015
[Chronic myelogenous leukemia]. Der Internist\| PubMed ID: 25860113	2015
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. Journal of cancer research and clinical oncology\| PubMed ID: 26002753	2015
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer\| PubMed ID: 26998677	2016
Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation... Hematology (Amsterdam, Netherlands)\| PubMed ID: 27311084	2017
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leukemia research\| PubMed ID: 27505637	2016
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 27856601	2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of cancer research and clinical oncology\| PubMed ID: 28224300	2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer\| PubMed ID: 28387926	2017
Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Leukemia\| PubMed ID: 29515237	2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood\| PubMed ID: 29567798	2018
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood\| PubMed ID: 29724897	2018
Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia\| PubMed ID: 30042412	2018
Human MAIT cells are rapidly activated by Aspergillus spp. in an APC-dependent manner. European journal of immunology\| PubMed ID: 30059139	2018
Fast and Quantitative Evaluation of Human Leukocyte Interaction with Aspergillus fumigatus Conidia by Flow Cytometry. Cytometry. Part A : the journal of the International Society for Analytical Cytology\| PubMed ID: 30450827	2019
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia\| PubMed ID: 31576004	2019